One Wealth Advisors LLC Has $1.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD

One Wealth Advisors LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.8% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 9,163 shares of the biopharmaceutical company’s stock after acquiring an additional 2,364 shares during the quarter. One Wealth Advisors LLC’s holdings in Gilead Sciences were worth $1,016,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after buying an additional 1,520,809 shares in the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $620,415,000. Finally, National Pension Service lifted its holdings in shares of Gilead Sciences by 6.9% during the 1st quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company’s stock worth $389,191,000 after acquiring an additional 223,171 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on GILD shares. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research note on Friday, August 8th. UBS Group upped their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Finally, JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $117.17.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider directly owned 113,193 shares of the company’s stock, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,000 shares of company stock valued at $8,285,530 in the last ninety days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Trading Up 0.5%

NASDAQ GILD opened at $112.62 on Tuesday. The company has a market cap of $139.74 billion, a price-to-earnings ratio of 22.43, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a twelve month low of $82.82 and a twelve month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business’s fifty day moving average is $114.50 and its 200 day moving average is $109.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.